A paper has recently been published in the Journal of Clinical Oncology showing the first results of the EURAMOS-1 trial. EURAMOS-1 is the largest osteosarcoma study ever conducted and UCLH was the largest contributor worldwide.

The standard treatment for osteosarcoma is intensive chemotherapy with MAP (methotrexate, doxorubicin and cisplatin), followed by surgery, followed by further chemotherapy with MAP. The EURAMOS-1 trial examined whether adding 18 months of extra treatment called interferon after the standard treatment could improve outcomes for patients with osteosarcoma. Interferon is produced naturally in the body, and has been found to be an effective treatment for some cancers.

The first results of the study relate to patients whose tumour had responded well to chemotherapy before their surgery. The results indicate that adding interferon after standard treatment does not improve outcomes for patients with osteosarcoma.

 For further information please see http://www.ctu.mrc.ac.uk/news/2015/euramos1_gr_results_02062015

 

< Back